Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01845740 · ClinicalTrials.gov registry record · Phase 1
Phase Ib Study of SC Milatuzumab in SLE
A Phase 1 study of Lupus Nephritis and Lupus Erythematosus, Systemic, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT01845740: Completed Phase 1 study of Lupus Nephritis and Lupus Erythematosus, Systemic, sponsored by Gilead Sciences.
NCT01845740 is a Phase 1 study of Lupus Nephritis and Lupus Erythematosus, Systemic that has completed, run by Gilead Sciences. The registered enrollment target is 22 participants, below the 310-participant average among 30 other Lupus Nephritis trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01845740, a Phase 1 study of Lupus Nephritis and Lupus Erythematosus, Systemic, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
Milatuzumab will be given subcutaneously at different dose levels once (depending on the dose level) for 4 weeks to determine if milatuzumab helps to control lupus (SLE).
Primary Outcome
Will be assessed using laboratory and clinical data comparing baseline lab results and clinical condition to the lab results and clinical condition/adverse events during treatment and follow-up timepoints up to 2 years.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG milatuzumab
Study Locations (1)
California
- Cedars Sinai Medical Center-Wallace Rheumatic Study Center - West Hollywood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2007-01 |
| Est. Completion | 2009-06 |
| Phase | Phase 1 |
What the finished NCT01845740 record still lists
NCT01845740 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 310-participant average among 30 other Lupus Nephritis trials with a reported enrollment target (93% lower).
The record links to 5 conditions, with Lupus Nephritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01845740 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01845740 about?
NCT01845740 is a clinical study titled "Phase Ib Study of SC Milatuzumab in SLE". Milatuzumab will be given subcutaneously at different dose levels once (depending on the dose level) for 4 weeks to determine if milatuzumab helps to control lupus (SLE).
What is the current status of trial NCT01845740?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2007-01. Estimated completion is 2009-06.
What conditions does trial NCT01845740 study?
This clinical trial studies the following conditions: Lupus Nephritis, Lupus Erythematosus, Systemic, Lupus Erythematosus, Discoid, Lupus Erythematosus, Cutaneous, Lupus Vasculitis, Central Nervous System.
What interventions are being tested in trial NCT01845740?
The interventions under investigation include: Placebo (DRUG), milatuzumab (DRUG).
Who is sponsoring clinical trial NCT01845740?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01845740 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lupus Nephritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01845740's enrollment target sits among peer trials
22 26th of 30 higher than 5 of 30 other Lupus Nephritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lupus Nephritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
RECRUITING · Phase 1
-
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
RECRUITING · Phase 1
-
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
RECRUITING · Phase 1
-
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
RECRUITING · Phase 1
-
A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old
ACTIVE NOT RECRUITING · Phase 1
-
KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia